To Get Full Access :

Vizz

Vizz is the first and only aceclidine-based eye drop approved for adults with presbyopia. Presbyopia is an age-related blurry near vision. By selectively contracting the iris sphincter muscle to create a pinhole effect and achieve a sub-2 mm pupil—without significant ciliary muscle stimulation—it extends depth of focus to provide fast, steroid-free relief of near-vision blur that lasts up to 10 hours. It offers a safe, once-daily, non-surgical alternative to traditional reading glasses and contact lenses.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Aceclidine
  • Innovator :

    LENZ THERAPEUTICS INC
  • Approval Date :

    31-Jul-25
  • NCE-1 Date :

    31-Jul-29
  • NCE Date :

    31-Jul-30
  • Dosage Form :

    Ophthalmic Solution/Drops
  • Strength :

    EQ 1.44% BASE
  • Therapeutic Category :

    Antiglaucoma Agents
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    4
  • 2026 :

    56
  • 2027 :

    148
  • 2028 :

    213
  • 2029 :

    284
  • 2030 :

    357
  • 2031 :

    428
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?